Literature DB >> 31376168

Imaging gradual neurodegeneration in a basal ganglia model disease.

Henrike Hanssen1,2, Jannik Prasuhn1,2, Marcus Heldmann1, Cid C Diesta3, Aloysius Domingo2,4, Martin Göttlich1, Anne J Blood5,6,7,8,9,10, Raymond L Rosales11, Roland D G Jamora12, Thomas F Münte1, Christine Klein2, Norbert Brüggemann1,2.   

Abstract

OBJECTIVE: X-linked dystonia-parkinsonism (XDP) is a neurodegenerative disease with adult onset dystonia and subsequent parkinsonism. Postmortem and imaging studies revealed remarkable striatal pathology, with a predominant involvement of the striosomal compartment in the early phase. Here, we aimed to disentangle sequential neurodegeneration in the striatum of XDP patients, provide evidence for preferential loss of distinct striatal areas in the early phase, and investigate whether iron accumulation is present.
METHODS: We used multimodal structural magnetic resonance imaging (voxel-based morphometry and relaxometry) in 18 male XDP patients carrying a TAF1 mutation and 19 age-matched male controls.
RESULTS: Voxel-based relaxometry and morphometry revealed (1) a cluster in the anteromedial putamen showing high iron content and severe atrophy (-55%) and (2) a cluster with reduced relaxation rates as a marker for increased water levels and a lower degree of atrophy (-20%) in the dorsolateral putamen. Iron deposition correlated with the degree of atrophy (ρ = -0.585, p = 0.011) and disease duration (ρ = 0.632, p = 0.005) in the anteromedial putamen. In the dorsolateral putamen, sensorimotor putamen atrophy correlated with disease severity (ρ = -0.649, p = 0.004).
INTERPRETATION: This multimodal approach identified a patchy pattern of atrophy within the putamen. Atrophy is advanced and associated with iron accumulation in rostral regions of the striatum, whereas neurodegeneration is moderate and still ongoing in dorsolateral areas. Given the short disease duration and predominant dystonic phenotype, these results are well in line with early and preferential degeneration of striosome-rich striatal areas in XDP. ANN NEUROL 2019;86:517-526.
© 2019 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.

Entities:  

Year:  2019        PMID: 31376168     DOI: 10.1002/ana.25566

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  6 in total

1.  GP2: The Global Parkinson's Genetics Program.

Authors: 
Journal:  Mov Disord       Date:  2021-01-29       Impact factor: 9.698

2.  Motor learning deficits in cervical dystonia point to defective basal ganglia circuitry.

Authors:  Sebastian Loens; Julius Verrel; Vera-Maria Herrmann; Amrei Kienzle; Elinor Tzvi; Anne Weissbach; Johanna Junker; Alexander Münchau; Tobias Bäumer
Journal:  Sci Rep       Date:  2021-04-01       Impact factor: 4.379

Review 3.  Dystonia updates: definition, nomenclature, clinical classification, and etiology.

Authors:  Karen Grütz; Christine Klein
Journal:  J Neural Transm (Vienna)       Date:  2021-02-19       Impact factor: 3.575

Review 4.  Contemporary functional neuroanatomy and pathophysiology of dystonia.

Authors:  Norbert Brüggemann
Journal:  J Neural Transm (Vienna)       Date:  2021-01-24       Impact factor: 3.575

Review 5.  Combined dystonias: clinical and genetic updates.

Authors:  Anne Weissbach; Gerard Saranza; Aloysius Domingo
Journal:  J Neural Transm (Vienna)       Date:  2020-10-24       Impact factor: 3.575

6.  TAF1 Transcripts and Neurofilament Light Chain as Biomarkers for X-linked Dystonia-Parkinsonism.

Authors:  Jamal Al Ali; Christine A Vaine; Shivangi Shah; Lindsey Campion; Ahmad Hakoum; Melanie L Supnet; Patrick Acuña; Gabrielle Aldykiewicz; Trisha Multhaupt-Buell; Niecy G M Ganza; John B B Lagarde; Jan K De Guzman; Criscely Go; Benjamin Currall; Bianca Trombetta; Pia K Webb; Michael Talkowski; Steven E Arnold; Pike S Cheah; Naoto Ito; Nutan Sharma; D Cristopher Bragg; Laurie Ozelius; Xandra O Breakefield
Journal:  Mov Disord       Date:  2020-09-25       Impact factor: 10.338

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.